Sucampo Pharmaceuticals Company Profile (NASDAQ:SCMP)

About Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SCMP
  • CUSIP: 86490910
  • Web: www.sucampo.com
Capitalization:
  • Market Cap: $511.1 million
  • Outstanding Shares: 46,464,000
Average Prices:
  • 50 Day Moving Avg: $10.49
  • 200 Day Moving Avg: $10.81
  • 52 Week Range: $9.30 - $17.55
P/E:
  • Trailing P/E Ratio: 18.33
  • Foreward P/E Ratio: 10.38
  • P/E Growth: 0.75
Sales & Book Value:
  • Annual Revenue: $239.13 million
  • Price / Sales: 2.10
  • Book Value: $4.01 per share
  • Price / Book: 2.69
Profitability:
  • EBIDTA: $128.05 million
  • Net Margins: 11.36%
  • Return on Equity: 43.27%
  • Return on Assets: 13.33%
Debt:
  • Debt-to-Equity Ratio: 1.67%
  • Current Ratio: 9.26%
  • Quick Ratio: 8.60%
Misc:
  • Average Volume: 447,948 shs.
  • Beta: 1.46
  • Short Ratio: 11.05
 
Frequently Asked Questions for Sucampo Pharmaceuticals (NASDAQ:SCMP)

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) issued its quarterly earnings results on Wednesday, May, 3rd. The company reported $0.23 EPS for the quarter, missing the Zacks' consensus estimate of $0.28 by $0.05. The business had revenue of $56.30 million for the quarter, compared to the consensus estimate of $54.15 million. Sucampo Pharmaceuticals had a return on equity of 43.27% and a net margin of 11.36%. The business's revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.21 earnings per share. View Sucampo Pharmaceuticals' Earnings History.

When will Sucampo Pharmaceuticals make its next earnings announcement?

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Sucampo Pharmaceuticals.

Where is Sucampo Pharmaceuticals' stock going? Where will Sucampo Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 1-year price targets for Sucampo Pharmaceuticals' stock. Their forecasts range from $11.00 to $27.00. On average, they expect Sucampo Pharmaceuticals' stock price to reach $17.17 in the next twelve months. View Analyst Ratings for Sucampo Pharmaceuticals.

What are analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, with acquisition of Vtesse, Sucampo added a late stage program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. The company has lowered its earnings guidance to incorporate the Vtesee acquisition." (7/4/2017)
  • 2. Maxim Group analysts commented, "Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $170M in cash & the rest in stock: total of $200M. There is also a contingent earn-out (payments in the mid-single digit to double-digit royalties on global net sales) of the product at increasing net sales levels." (4/3/2017)
  • 3. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
  • 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Who are some of Sucampo Pharmaceuticals' key competitors?

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:

  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer
  • Peter P. Pfreundschuh CPA, Chief Financial Officer, Principal Financial Officer
  • Matthias Alder, Executive Vice President
  • Max Donley, Executive Vice President of Human Resources
  • Thomas J. Knapp, Executive Vice President, Chief Legal Officer and Corporate Secretary
  • Stanley G. Miele, Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
  • Peter A. Kiener Ph.D., Chief Scientific Officer
  • Alex Driggs, Acting General Counsel, Corporate Secretary
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer
  • John H. Johnson, Lead Independent Director

Who owns Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (2.71%), Bowling Portfolio Management LLC (0.29%), Municipal Employees Retirement System of Michigan (0.26%), Malaga Cove Capital LLC (0.18%), Adams Diversified Equity Fund Inc. (0.14%) and Strs Ohio (0.13%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Matthias Alder and Peter Greenleaf. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Who sold Sucampo Pharmaceuticals stock? Who is selling Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Affinity Investment Advisors LLC, Bank of Montreal Can, Russell Investments Group Ltd. and Malaga Cove Capital LLC. Company insiders that have sold Sucampo Pharmaceuticals stock in the last year include Andrew P Smith, Daniel P Getman, Matthias Alder and Peter Greenleaf. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Who bought Sucampo Pharmaceuticals stock? Who is buying Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Municipal Employees Retirement System of Michigan, Bowling Portfolio Management LLC, Strs Ohio, Adams Diversified Equity Fund Inc., First Citizens Bank & Trust Co., Capstone Asset Management Co. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Sucampo Pharmaceuticals.

How do I buy Sucampo Pharmaceuticals stock?

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $10.80.


MarketBeat Community Rating for Sucampo Pharmaceuticals (NASDAQ SCMP)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sucampo Pharmaceuticals (NASDAQ:SCMP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $17.17 (58.95% upside)

Analysts' Ratings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/4/2017Jefferies Group LLCLower Price TargetHold$13.00 -> $11.00MediumView Rating Details
4/13/2017Maxim GroupReiterated RatingBuy$21.00MediumView Rating Details
4/4/2017MizuhoReiterated RatingBuy$14.00HighView Rating Details
3/11/2017Roth CapitalSet Price TargetBuy$27.00MediumView Rating Details
3/10/2017WallachBeth CapitalLower Price TargetBuy$20.00 -> $15.00LowView Rating Details
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00N/AView Rating Details
5/4/2016GuggenheimReiterated RatingBuy$29.00N/AView Rating Details
3/17/2016Leerink SwannReiterated RatingMarket Perform$17.00N/AView Rating Details
11/6/2015HC WainwrightLower Price Target$36.00 -> $28.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Earnings by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Earnings History by Quarter for Sucampo Pharmaceuticals (NASDAQ SCMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017$0.27N/AView Earnings Details
5/3/2017Q1 2017$0.28$0.23$54.15 million$56.30 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.48$0.68$66.00 million$73.00 millionViewListenView Earnings Details
11/9/2016Q316$0.26$0.28$51.30 million$57.90 millionViewListenView Earnings Details
8/3/2016Q216$0.22$0.23$48.33 million$52.00 millionViewListenView Earnings Details
5/4/2016Q116$0.19$0.21$44.11 million$47.20 millionViewListenView Earnings Details
3/8/2016Q415$0.19$0.43$42.72 million$55.40 millionViewListenView Earnings Details
11/4/2015Q315$0.18$0.16$36.18 million$33.50 millionViewListenView Earnings Details
8/5/2015Q215$0.15$0.21$31.90 million$34.90 millionViewListenView Earnings Details
5/6/2015Q114$0.14$0.14$30.19 million$29.50 millionViewListenView Earnings Details
3/4/2015Q413$0.17$0.21$37.23 million$37.80 millionViewListenView Earnings Details
11/6/2014Q313$0.04$0.03$26.11 million$31.50 millionViewListenView Earnings Details
8/5/2014Q213$0.03$0.04$24.06 million$24.10 millionViewListenView Earnings Details
5/7/2014Q113$0.04$0.02$24.19 million$22.20 millionViewListenView Earnings Details
2/26/2014Q4($0.04)$0.06$22.75 million$24.50 millionViewListenView Earnings Details
3/13/2013Q4 2012$0.12$0.32$32.21 million$34.90 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)
2017 EPS Consensus Estimate: $1.07
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.23$0.29$0.25
Q2 20172$0.22$0.26$0.24
Q3 20172$0.26$0.27$0.27
Q4 20172$0.29$0.33$0.31
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Insider Ownership Percentage: 4.13%
Institutional Ownership Percentage: 56.10%
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Daniel P GetmanDirectorSell20,000$16.86$337,200.00View SEC Filing  
11/29/2016Peter GreenleafCEOSell200,000$16.84$3,368,000.00View SEC Filing  
11/28/2016Matthias AlderEVPSell150,000$16.00$2,400,000.00View SEC Filing  
11/15/2016Andrew P SmithCFOSell1,766$15.58$27,514.28View SEC Filing  
8/28/2015Daniel P. GetmanDirectorSell30,000$28.14$844,200.00View SEC Filing  
7/20/2015Thomas J KnappInsiderSell64,528$23.43$1,511,891.04View SEC Filing  
3/12/2015William AshtonDirectorSell55,762$17.55$978,623.10View SEC Filing  
3/11/2015Anthony C CelesteDirectorSell65,966$17.34$1,143,850.44View SEC Filing  
12/16/2014Cary J ClaiborneCFOSell50,000$12.91$645,500.00View SEC Filing  
12/15/2014Cary J ClaiborneCFOSell7,100$12.89$91,519.00View SEC Filing  
8/7/2014Sachiko KunoMajor ShareholderSell181,727$6.28$1,141,245.56View SEC Filing  
8/4/2014Ryuji UenoMajor ShareholderSell140,873$6.02$848,055.46View SEC Filing  
7/31/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/30/2014S&R Technology Holdings, LlcMajor ShareholderSell300$6.25$1,875.00View SEC Filing  
7/25/2014Ryuji UenoMajor ShareholderSell16,155$6.26$101,130.30View SEC Filing  
7/23/2014Ryuji UenoMajor ShareholderSell5,845$6.29$36,765.05View SEC Filing  
7/22/2014S&R Technology Holdings, LlcMajor ShareholderSell2,500$6.25$15,625.00View SEC Filing  
7/21/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/18/2014S&R Technology Holdings, LlcMajor ShareholderSell15,000$6.27$94,050.00View SEC Filing  
4/29/2014S&R Technology Holdings, Llcmajor shareholderSell113,600$6.65$755,440.00View SEC Filing  
4/25/2014Sachiko Kunomajor shareholderSell118,700$6.69$794,103.00View SEC Filing  
3/18/2014Gayle DolecekDirectorSell1,200$8.03$9,636.00View SEC Filing  
2/27/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
1/17/2014Ryuji UenoCEOSell360,000$10.36$3,729,600.00View SEC Filing  
1/7/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
10/16/2013Sachiko KunoMajor ShareholderSell360,000$6.35$2,286,000.00View SEC Filing  
9/18/2013Ryuji UenoCEOSell38,462$5.69$218,848.78View SEC Filing  
9/3/2013Ryuji UenoCEOSell38,462$5.59$215,002.58View SEC Filing  
8/19/2013Ryuji UenoCEOSell38,462$6.04$232,310.48View SEC Filing  
8/6/2013Sachiko Kunomajor shareholderSell38,462$6.21$238,849.02View SEC Filing  
7/24/2013Ryuji UenoCEOSell38,462$6.52$250,772.24View SEC Filing  
7/9/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.48$249,233.76View SEC Filing  
6/24/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.61$254,233.82View SEC Filing  
6/10/2013Sachiko KunoMajor ShareholderSell38,462$7.29$280,387.98View SEC Filing  
5/28/2013Ryuji UenoCEOSell38,462$8.79$338,080.98View SEC Filing  
5/21/2013Cary J ClaiborneCFOSell4,640$9.52$44,172.80View SEC Filing  
5/20/2013Stanley G MieleSVPSell6,400$9.60$61,440.00View SEC Filing  
5/16/2013Stanley G MieleSVPSell48,600$9.67$469,962.00View SEC Filing  
5/15/2013Timothy I MaudlinDirectorBuy32,870$9.82$322,783.40View SEC Filing  
5/13/2013Sachiko KunoMajor ShareholderSell38,462$9.27$356,542.74View SEC Filing  
2/4/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$5.22$200,771.64View SEC Filing  
12/26/2012S&R Technology Holdings, LlcMajor ShareholderSell20,262$5.01$101,512.62View SEC Filing  
11/27/2012Sachiko KunoMajor ShareholderSell12,205$5.00$61,025.00View SEC Filing  
11/13/2012Sachiko KunoMajor ShareholderSell11,962$5.00$59,810.00View SEC Filing  
11/1/2012Sachiko KunoMajor ShareholderSell37,595$5.06$190,230.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Latest Headlines for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Source:
DateHeadline
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:41 AM
globenewswire.com logoSucampo Announces Second Quarter 2017 Earnings Call - GlobeNewswire (press release)
globenewswire.com - July 20 at 7:33 AM
finance.yahoo.com logoSucampo Announces Second Quarter 2017 Earnings Call
finance.yahoo.com - July 20 at 7:33 AM
streetinsider.com logoSucampo Pharma (SCMP) Names Karen Smith to Board of Directors - StreetInsider.com
www.streetinsider.com - July 19 at 7:38 AM
streetinsider.com logoSucampo Pharma (SCMP) Names Karen Smith to Board of Directors
www.streetinsider.com - July 19 at 7:38 AM
finance.yahoo.com logoDr. Karen Smith Joins Sucampo’s Board of Directors
finance.yahoo.com - July 19 at 7:38 AM
americanbankingnews.com logo$0.22 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - July 12 at 10:38 PM
finance.yahoo.com logoETFs with exposure to Sucampo Pharmaceuticals, Inc. : July 11, 2017
finance.yahoo.com - July 12 at 7:44 AM
finance.yahoo.com logoSucampo (SCMP) Remains Focused on Amitza Label Expansion
finance.yahoo.com - July 6 at 8:47 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 4 at 1:07 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 4 at 9:18 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - June 24 at 12:06 AM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : June 22, 2017
finance.yahoo.com - June 22 at 12:45 PM
finance.yahoo.com logoETFs with exposure to Sucampo Pharmaceuticals, Inc. : June 19, 2017
finance.yahoo.com - June 20 at 6:37 AM
americanbankingnews.com logo$57.01 Million in Sales Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - June 18 at 8:14 AM
americanbankingnews.com logo Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.22 EPS
www.americanbankingnews.com - June 16 at 10:22 PM
finance.yahoo.com logo3 Hiddem Gems in the Healthcare Sector
finance.yahoo.com - June 16 at 4:02 PM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 4:02 PM
streetinsider.com logoSucampo Pharma (SCMP) Receives New Patent for VTS-270
www.streetinsider.com - June 14 at 12:47 AM
streetinsider.com logoSucampo Pharma (SCMP) Receives New Patent for VTS-270 - StreetInsider.com
www.streetinsider.com - June 13 at 7:47 PM
finance.yahoo.com logoSucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
finance.yahoo.com - June 13 at 7:47 PM
nasdaq.com logoWhy Is Sucampo (SCMP) Up 1.5% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 10 at 12:57 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 9 at 9:52 AM
finance.yahoo.com logoWhy Is Sucampo (SCMP) Up 1.5% Since the Last Earnings Report?
finance.yahoo.com - June 8 at 2:55 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Lowered to Hold at ValuEngine
www.americanbankingnews.com - June 3 at 11:32 AM
globenewswire.com logoSucampo Pharmaceuticals Announces Webcast of Its Presentation ... - GlobeNewswire (press release)
globenewswire.com - June 1 at 10:42 PM
finance.yahoo.com logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 10:42 PM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : May 29, 2017
finance.yahoo.com - May 29 at 6:39 PM
seekingalpha.com logoSucampo Pharmaceuticals (SCMP) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 23 at 7:08 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 15 at 11:10 AM
finance.yahoo.com logoCerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
finance.yahoo.com - May 15 at 9:29 AM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : May 12, 2017
finance.yahoo.com - May 12 at 8:24 PM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : May 11, 2017
finance.yahoo.com - May 11 at 8:11 PM
finance.yahoo.com logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 11 at 8:11 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Forecasted to Earn FY2017 Earnings of $1.01 Per Share
www.americanbankingnews.com - May 8 at 9:38 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Sucampo Pharmaceuticals, Inc. Cut by Jefferies Group (SCMP)
www.americanbankingnews.com - May 5 at 8:02 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - May 4 at 1:20 PM
finance.yahoo.com logoSucampo Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 12:12 AM
finance.yahoo.com logoEdited Transcript of SCMP earnings conference call or presentation 3-May-17 12:30pm GMT
finance.yahoo.com - May 4 at 12:12 AM
finance.yahoo.com logoInvestor Network: Sucampo Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 7:11 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Posts Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 3 at 6:04 PM
marketbeat.com logoSucampo tops 1Q revenue forecasts
marketbeat.com - May 3 at 7:02 AM
americanbankingnews.com logoSomewhat Favorable Press Coverage Likely to Affect Sucampo Pharmaceuticals (SCMP) Stock Price
www.americanbankingnews.com - May 3 at 1:03 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) to Release Earnings on Wednesday
www.americanbankingnews.com - May 1 at 7:42 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Earnings of $0.25 Per Share
www.americanbankingnews.com - April 29 at 1:22 AM
americanbankingnews.com logoSucampo Pharmaceuticals (SCMP) Getting Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 27 at 6:14 PM
americanbankingnews.com logoLeerink Swann Equities Analysts Decrease Earnings Estimates for Sucampo Pharmaceuticals, Inc. (SCMP)
www.americanbankingnews.com - April 27 at 1:00 PM
finance.yahoo.com logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 26 at 9:01 PM
thestreet.com logoCommit To Buy Sucampo Pharmaceuticals At $7.50, Earn 17% Annualized Using Options - TheStreet.com
www.thestreet.com - April 26 at 4:00 PM
finance.yahoo.com logoETFs with exposure to Sucampo Pharmaceuticals, Inc. : April 26, 2017
finance.yahoo.com - April 26 at 4:00 PM

Social

Chart

Sucampo Pharmaceuticals (SCMP) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff